Holen Sie sich die Stockscreener-App
72.74
1.29%
-0.95
Handel nachbörslich:
72.00
-0.74
-1.02%
Schlusskurs vom Vortag:
$73.69
Offen:
$73.5
24-Stunden-Volumen:
2.76M
Relative Volume:
1.25
Marktkapitalisierung:
$13.25B
Einnahmen:
$381.03M
Nettoeinkommen (Verlust:
$-1.01B
KGV:
-12.23
EPS:
-5.95
Netto-Cashflow:
$-789.25M
1W Leistung:
+5.10%
1M Leistung:
+0.22%
6M Leistung:
-3.44%
1J Leistung:
+25.78%
1-Tages-Spanne:
$72.31
$74.98
1-Wochen-Bereich:
$67.81
$74.98
52-Wochen-Spanne:
$55.74
$84.91
Insmed Inc Stock (INSM) Company Profile
Firmenname
Insmed Inc
Sektor
Branche
Telefon
908-977-9900
Adresse
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Vergleichen Sie INSM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
72.74 | 12.61B | 381.03M | -1.01B | -789.25M | -5.95 |
|
ONC
Beone Medicines Ltd Adr
|
257.00 | 26.69B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.82 | 114.81B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.282 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
85.54 | 6.60B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
483.07 | 65.36B | 14.09B | 4.50B | 2.96B | 39.28 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-13 | Eingeleitet | Jefferies | Buy |
| 2025-02-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-04-23 | Eingeleitet | Truist | Buy |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-07-26 | Eingeleitet | Guggenheim | Buy |
| 2022-12-09 | Eingeleitet | Mizuho | Buy |
| 2022-12-07 | Eingeleitet | Barclays | Overweight |
| 2022-11-18 | Eingeleitet | BofA Securities | Buy |
| 2022-04-27 | Eingeleitet | Goldman | Buy |
| 2021-12-06 | Eingeleitet | JP Morgan | Overweight |
| 2021-10-19 | Fortgesetzt | Monness Crespi & Hardt | Buy |
| 2021-10-19 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-10-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-12-17 | Eingeleitet | Berenberg | Buy |
| 2020-10-12 | Fortgesetzt | Stifel | Buy |
| 2019-09-03 | Eingeleitet | Goldman | Buy |
| 2019-04-09 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-15 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-01-17 | Hochstufung | Goldman | Neutral → Buy |
| 2019-01-02 | Eingeleitet | Canaccord Genuity | Buy |
| 2018-08-06 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-07-23 | Eingeleitet | Goldman | Neutral |
| 2018-04-23 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2018-03-21 | Eingeleitet | Morgan Stanley | Overweight |
| 2018-01-18 | Eingeleitet | Credit Suisse | Neutral |
| 2017-09-05 | Bestätigt | Evercore ISI | Outperform |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-07-11 | Eingeleitet | Robert W. Baird | Outperform |
| 2016-03-15 | Eingeleitet | Stifel | Buy |
| 2015-11-09 | Herabstufung | UBS | Buy → Neutral |
| 2015-10-06 | Bestätigt | H.C. Wainwright | Buy |
| 2015-06-09 | Eingeleitet | Citigroup | Neutral |
| 2014-03-26 | Bestätigt | HC Wainwright | Buy |
Alle ansehen
Insmed Inc Aktie (INSM) Neueste Nachrichten
Organizational Transitions, Patient Enrollment, Initiation of Clinical Programs, Financial Outlook, and Corporate UpdatesA... - ADVFN
Insider Sell Alert: MCGIRR DAVID W J Sells 6,250 Shares of Insme - GuruFocus
INSMED Executives Conduct Series of Stock Transactions - TradingView
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | INSM Stock News - GuruFocus
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - marketscreener.com
Insmed Accelerates Growth: 150 New Hires Receive $10M+ in Stock Awards and Options - Stock Titan
Insider Sell: Michael Smith Sells 26,327 Shares of Insmed Inc (I - GuruFocus
Insmed Breaks Above 200-Day Moving AverageBullish for INSM - Nasdaq
If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today - Benzinga
Insmed To Present at the 2025 Goldman Sachs Annual Global Health - GuruFocus
Insmed To Present at the 2025 Goldman Sachs Annual Global Healthcare Conference - marketscreener.com
Insmed’s SWOT analysis: rare disease biotech stock shows promise amid challenges - Investing.com
Insmed Incorporated (NASDAQ:INSM) Shares Purchased by Cetera Investment Advisers - Defense World
8MM Bronchiectasis Market Opportunity Assessment and Forecasts, 2033 - GlobeNewswire Inc.
Insmed Says Brensocatib Showed Consistent Efficacy in Non-Cystic Fibrosis Bronchiectasis - marketscreener.com
Insmed (INSM) Highlights Promising Brensocatib Trial Results at - GuruFocus
Insmed (INSM) Highlights Promising Brensocatib Trial Results at ATS 2025 | INSM Stock News - GuruFocus
Brensocatib Shows Consistent Efficacy and Safety Across Three Prespecified Subgroups in New Data from Landmark ASPEN Study - Yahoo Finance
Captrust Financial Advisors Sells 631 Shares of Insmed Incorporated (NASDAQ:INSM) - Defense World
Mercer Global Advisors Inc. ADV Acquires New Position in Insmed Incorporated (NASDAQ:INSM) - Defense World
HC Wainwright Issues Optimistic Outlook for Insmed Earnings - Defense World
INSMED Executives Sell Shares to Satisfy Tax Obligations - TradingView
Jefferies Financial Group Initiates Coverage on Insmed (NASDAQ:INSM) - Defense World
Jefferies Initiates Coverage of Insmed (BIT:1INSM) with Buy Recommendation - Nasdaq
Insmed Incorporated (INSM): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying - Insider Monkey
Jefferies Initiates Coverage of Insmed (BMV:INSM) with Buy Recommendation - Nasdaq
Jefferies sets $105 target on Insmed stock with Buy rating By Investing.com - Investing.com Nigeria
Insmed at Bank of America 2025 Healthcare Conference: Strategic Pipeline Focus - Investing.com
Jefferies Initiates Coverage on INSM with a Buy Rating and $105 PT | INSM Stock News - GuruFocus
Jefferies Initiates Coverage of Insmed (LSE:0JAV) with Buy Recommendation - Nasdaq
Unlocking Insmed (INSM) International Revenues: Trends, Surprises, and Prospects - Yahoo Finance
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Jefferies Initiates Coverage of Insmed (INSM) with Buy Recommendation - Nasdaq
Jefferies Initiates Coverage on Insmed With Buy Rating, $105 Price Target - marketscreener.com
Jefferies sets $105 target on Insmed stock with Buy rating - Investing.com
Insmed (NASDAQ:INSM) Given Buy Rating at HC Wainwright - Defense World
Insmed (INSM) Gains Buy Rating from Jefferies with Promising Out - GuruFocus
Insmed (INSM) Receives Reaffirmed Buy Rating from HC Wainwright - GuruFocus
Analyst Expectations For Insmed's Future - Benzinga
Insmed Incorporated (NASDAQ:INSM) Given Consensus Rating of “Buy” by Analysts - Defense World
UBS Group Cuts Insmed (NASDAQ:INSM) Price Target to $109.00 - Defense World
Insmed (INSM) Reports Q1 Loss, Tops Revenue Estimates - MSN
Analysts Are Updating Their Insmed Incorporated (NASDAQ:INSM) Estimates After Its First-Quarter Results - Yahoo Finance
Insmed Incorporated (NASDAQ:INSM) Q1 2025 Earnings Call Transcript - Insider Monkey
Insmed (INSM) Receives Slight Price Target Adjustment by UBS | I - GuruFocus
UBS Maintains Buy Rating, Lowers Price Target for Insmed (INSM) - GuruFocus
Insmed's Q1 Loss Wider Than Expected, Sales Match Estimates - TradingView
$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today - Benzinga
Is Insmed Incorporated (INSM) the Best Cancer Stock to Invest in for Long-Term Gain? - Insider Monkey
Insmed (INSM) Receives Slight Price Target Adjustment by UBS | INSM Stock News - GuruFocus
RBC Trims Price Target on Insmed to $99 From $100, Keeps Outperform Rating - marketscreener.com
Finanzdaten der Insmed Inc-Aktie (INSM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Insmed Inc-Aktie (INSM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Flammer Martina M.D. | Chief Medical Officer |
Jun 03 '25 |
Sale |
71.50 |
1,686 |
120,549 |
83,111 |
| Adsett Roger | Chief Operating Officer |
Jun 03 '25 |
Sale |
71.50 |
1,860 |
132,990 |
141,323 |
| Bonstein Sara | Chief Financial Officer |
Jun 03 '25 |
Sale |
71.50 |
1,579 |
112,898 |
113,288 |
| Schaeffer Orlov S Nicole | Chief People Strategy Officer |
Jun 03 '25 |
Sale |
71.50 |
1,642 |
117,403 |
118,579 |
| MCGIRR DAVID W J | Director |
Jun 03 '25 |
Sale |
71.30 |
3,250 |
231,725 |
100,723 |
| MCGIRR DAVID W J | Director |
Jun 04 '25 |
Sale |
73.27 |
3,000 |
219,810 |
97,723 |
| Lewis William | Chair and CEO |
Jun 02 '25 |
Option Exercise |
10.85 |
6,830 |
74,106 |
240,754 |
| Lewis William | Chair and CEO |
Jun 02 '25 |
Sale |
71.31 |
6,830 |
487,044 |
233,924 |
| Lewis William | Chair and CEO |
Jun 03 '25 |
Sale |
71.50 |
5,472 |
391,248 |
308,758 |
0.86%
1.24%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):